Oral Mucositis
Oral Mucositis, a debilitating side effect of cancer therapy, is finally being addressed through preventative biophotonics. In 2026, patients undergoing high-dose chemotherapy are prescribed "Light-Emitting Mouthguards" that deliver low-level laser therapy (LLLT) to the oral mucosa. This treatment stimulates cellular repair and reduces oxidative stress before the ulcers can form. This has drastically improved the quality of life for oncology patients, allowing them to maintain proper nutrition and avoid the high-dose opioids previously required for mouth pain.
Beyond light therapy, the development of "Bio-adhesive Muco-protectants" has provided a new layer of defense. These are synthetic polymers that mimic the mouth's natural mucus, creating a long-lasting physical barrier over sensitive tissues. Some of these gels are now "bio-active," containing growth factors that actively signal the mucosal lining to regenerate. By preventing the severe infection risks associated with open mouth sores, these treatments ensure that cancer patients can complete their primary treatments without life-threatening interruptions.